| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_790110ba53d6d143fd2c7f2ca50abbee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10e4b1416c6e66e0ade5429212414964 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 |
| filingDate |
2013-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f304a083e171fe712878dddb4b2bc6a2 |
| publicationDate |
2013-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013303569-A1 |
| titleOfInvention |
Use of high dose laquinimod for treating multiple sclerosis |
| abstract |
Disclosed herein are methods of treating a human patient afflicted with multiple sclerosis (MS) or presenting a clinically isolated syndrome (CIS), for treating a human subject by providing neuroprotection, and of treating a human patient afflicted with MS or presenting a CIS by increasing the time to confirmed disease progression and/or confirmed relapse or reducing brain atrophy, comprising orally administering a daily dose of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof. Also disclosed is a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in treating a human patient afflicted with MS or presenting a CIS, in treating a human subject by providing neuroprotection, or in treating a human patient afflicted with MS or presenting a CIS by increasing the time to confirmed disease progression and/or confirmed relapse or reducing brain atrophy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9161935-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9662322-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8975279-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014058979-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9284276-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9233927-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017027512-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015168103-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015100365-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8889627-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11654140-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9161936-B2 |
| priorityDate |
2012-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |